布列维尔提德在慢性肝炎D等待肝移植的患者中的治疗结果来自法国多中心回顾性研究
Magdalena Meszaros1, Marie-Noëlle Hilleret2, Jérôme Dumortier3
1Liver Transplantation and Hepatogastroenterology Unit, CHU Montpellier, CHU Montpellier, Montpellier, France.
概括
布列维尔提德对慢性肝炎三角病毒 (HDV) 等待肝移植 (LT) 的患者有希望. 治疗改善了病毒学和生化反应,可能提高了移植前的结果和生存率.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 移植医学 移植医学
背景情况:
- 布莱维尔提德在慢性肝炎三角病毒 (HDV) 等待肝移植 (LT) 患者的疗效对于脱补偿性肝病或肝细胞癌 (HCC) 仍然不清楚.
- 评估布莱维对这种患者群体的临床,病毒学和生化反应的影响至关重要.
研究的目的:
- 为了评估临床,病毒学和生化反应,在等待LT的高强度病毒感染患者中对布莱维尔提德进行评估.
- 为了比较布莱维尔提德治疗患者的结果与类似未经治疗患者的队列.
主要方法:
- 包括一组连续感染高强度病毒的等待LT的患者.
- 患者每天接受2毫克布莱维,数据收集在基线,第24周,第48周,在LT和后LT.
- 一个未经治疗的对照组在基线,LT和LT后收集数据进行比较.
主要成果:
- 布列维尔提德治疗导致48周后HDVRNA的中位数下降2.56 log IU/mL (p=0.004).
- 病毒学和生化反应分别在73.3%和66.6%的患者中观察到.
- 与未接受治疗的组相比,布莱维类药物组的无移植生存期显著更高 (76.9%与36.7%,p=0.007).
结论:
- 布列维尔提德在LT等候名单上的高强度病毒感染患者中是安全有效的.
- 这种治疗可以改善移植前的结果,包括使化学栓塞等手术成为可能,并导致患者退出医疗清单.
- 布莱维尔提德在这个关键患者群体中显示出改善无移植生存的潜力.
更多相关视频
相关概念视频
Diseases of the Liver and Gallbladder
2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
274
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
387
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
387
Hepatitis
99
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
99
Viral Hepatitis I: Introduction
28
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
28


